



Innovative Medicines Initiative

Zoonoses Anticipation and Preparedness Initiative

Jean-Christophe Audonnet DVM, Ph.D. ZAPI IMI Project Coordinator

How to deliver vaccines and therapeutic antibodies under very short timelines ?



COPIL RFSA, June18th, 2018, Paris, France



Zoonoses Anticipation and Preparedness Initiative











IMI Basic Principles



Key concepts underlying IMI



Non-competitive collaboration between large pharma companies

A new ecosystem for sustainable healthcare across Europe, involving all stakeholders



3





Public consortium partners:

EFPIA partners :

Erasmus Medical Center NL WBVR Lelystad NL Utrecht University NL Leyden University NL FLI Riems DE Institut Pasteur FR IABS-EU FR / BE

Merial (now part of Boehringer Ingelheim)

Univ. Klin. Bonn DE Viroclinics Biosciences NL CSIC Madrid SP IRTA-CReSA SP TiHo Hannover DE Aix-Marseille Univ. FR



۲

lacksquare

Dyadic NDL Wageningen NL Harbour Antibodies Rotterdam NL Artemis NL Finovatis FR



EFPIA coordinator



The Reason for ZAPI: facing the unknown, and the need to be able to react rapidly

dal des

ton trial used

e (2), or for alapti

to meet the logistical chal te disease and the populations is

is spreading (10). Adaptive designs

multirie candidate vaccines and

resources toward those showing

omise may be needed, particu

rging-disease vaccines to avoid s that could arise in testing vac-

te has been proven effective. The

such trial designs should be un-

serging infectious disease

s pose novel ethical ques-

domized or placebo-con-

a different spe

al infection (1), Zika

s As with trial design.

fort is needed, dur-

hen there is not an

reney, to raise. each consensus

es that can arise

alyti Ser.

osuns, For

ns under

sed in

efforts

othics

ad by

w dif-

Health Orga-

trolled trials in the context of a

they are needed.

tions For Ebola there was an intense debate thout the ethics and political acceptability



INSIGHTS

PERSPECTIVES

INFECTIOUS DISEASE

Zika vaccine trials

There are new and familiar challenges in the race for timely and effective vaccines

By Mare Lipsitch' and Benjamin J. Cowling*

mising data for candidate vaccinminst Zka virus infection reported by Alibinket al. (1) on page 1129 of this issue mise hopes that one or more Zika virus vaccines may soon be ready for efficacy trials. Recent years have seen a harrage of emerging infectious diseases, including those caused by new mathogens such as Middle East respiratory syndrome (MERS) coronavirus, and those that are

newly salient because of increased geographic spread, higher incidence, or genetic change, such as influenza A(H1N1)plm09, Eboia virus, and Zika virus. Developing effective vaccines is a central goal for such pathogens.

emerging intercaught us by su able. Human safety and immu nogenicity must be established before starting large-scale efficacy studies. These studies consumvaluable time while the endemit spreads During the 2014-2015 Ebola epidemic, the urgency of exponentially growing incidence gave way to the urgency of declin ing incidence, which threatened the shifty to test varrine off.

cars The effectiveness of one Eboia vaccine was proven just as the epidemic ended (2). During the 2009-2010 influence A/H1N0 pandemic efficacy testing was not required because demonstrating immunogenidty for influenza vaccines is accepted as indicative of efficacy (3). Not, delays in vaccine availability ions meant that the vaccine a d too late to affect the course of the first

Center the Communicable Disease Dynamics, Department of Epidemiology, Harvard TH, Chan School of Public Health, Doctory, MAJEA. Monthleads Organization Calification Brg Centre for Interface Disease Dis denied age and Control School of Malic Heads, UKa Shing Readly of Medication, The University of Hange Kong Nang Kang David miljositelith sph harvards da

proorforming human safety and immunoge nicky studies on candidate vaccines against



figure emergencies caus ferent types of pathogens bunched a sofetyand immunogenicity clinical trial of a vaccine condidate to prevent Zika vitus infection Many challenges for

vaccines arose from the a range of pathogens before the next emer- ity of the infection. Zika virus infec gency (5, 6) would enhance preparedness by contrast, is mild or asymptomatic against known nathogons that could become most nations hut severe in a few, can greater threats if they become more common orgenital malformations in the fetuses ome women infected during program or geographically widespread Moreover, for pathogens (3, 7) that have at least one proven (B) This pattern misss distinct challenges efficacious vaccine, discovering correlates of What is the most relevant out come for clin protection (8) could justify initial reliance caltrials? We do not yet know how much a on immunogenicity (and safety) data in the nild or asymptomatic infection contributes use of subsequent vaccines or formulations o transmission or whether it could have against the same rathogen. The new field of etuses if it occurs in a prognant woman. systems vaccinology which uses thousands refore, infection, rather than symptoms, of measurements on vaccinated persons to could be an important trial end point. Howidentify correlates and possible mechanisms ever, this raises challenges for monitoring of immune protection (9), could accelerate trial participants, especially because serologic tests for 2ka virus infection are im-

calk for

the ring-v

larly fo

ethical

ines afte

promenties.

derstood b

up for the

Trials for

idually

highly

ing a

debate,

shout othics

in trials of co

example, the Wor visation defined o

which placebos o

vaccine tefals (12).

will require not only

and openness to

spectives, but also i

to anticipate distinct

challenges that could be

challeng

admontag.org SCIENCE

By Marc Lipsitch¹ and sciencemag.org SCIENCE Benjamin J. Cowling²

such discovery.

1094 9 SEPTEMBER 2016 • VOL 353 ISSUE 6304

A key principle of preparedness is to do as much work as possible before an emergency happens, so that the response can be decisive and efficient. Several approaches would speed vaccine availability in future emergencies. For pathogens we have not yet encountered, there is a need for platform technologies that produce test vaccine lots and, if successful, mass-produce vaccines against a new pathogen (4). Further, innovative proposals

Continued innovation during "peacetime" designing and studying (through simulavaccine efficacy trials that address the challenges of emergencies is needed to ennance quick responses. Getting results rap-






ZAPI Overall Objectives



- ZAPI's outcome will be a methodology which works for several targets.
- ZAPI will provide a technology and selection method for the industrialization of therapeutic / preventive solutions.
- ZAPI will provide a methodology which will enable fast manufacturing and batch release, avoiding to stockpile.
- ZAPI aims at providing effective tools that will stop the disease progress in animals before it spreads to humans.







Prototyping ZAPI methodology with 3 viral models



- 3 <u>"zoonotic" viral models</u> are used in the ZAPI project:
 - Rift Valley Fever Virus (RVFV) (Bunyaviridiae, Phlebovirus)
 - Schmallenberg Virus (SBV) (Bunyaviridae, Orthobunyavirus)
 - MERS-CoV (Betacoronavirus)
- 2 main targets for ZAPI Vaccines:
 - RVFV and SBV (MERS-CoV evaluated at small scale only)
- 2 main targets for ZAPI Therapeutic Antibodies: — MERS-CoV and RVFV





Objectives & Challenges for ZAPI Vaccines Strategy



- Define key immunogen subunits which are:
 - Large enough to bear key protective epitopes and to be immunogenic
 - Small enough to be soluble / secreted at high yields in vitro
 - Well defined / characterized by specific antibodies

Design manufacturing process which can :


- achieve « surge capacity » (millions of doses in a few weeks)
- be deployed easily






Can we identify immunogenic subunit domains?





GcAmino













Figure 1. Schematic representation of MERS-CoV S protein. The signal peptide (SP), receptor binding domair


10




protein scaffold particles (MPSP) The growing world of multimeric



Lumazine Synthase Aquifex aeolicus or Brucella spp



Aldolase 13-01 artificial protein



Entrez 3D Structure database








ZAPI Presentation COPIL RFSA June 2018


Modular scaffold system with bacterial superglue





ZAPI as a « serious game » methodology
















Coupling immunogens / MPSP to generate vaccine complexes



- Stand alone subunit formulated with an adjuvant may work as such
- ZAPI vaccine complex modular methodology should provide a number of advantages:
 - Robustness in manufacturing
 - Stability (thermostability of the core NP)
 - Efficient targeting of DCs and lymph nodes
 - Quality of the protective immune response







Regulatory aspects

- Acceptability of new platforms under emergency situations
 - MPSP-subunit « platforms » versus live vaccines or live vectors
 - Actual implementation of the « animal rule » for ZAPI methodology-based vaccines and neutralizing antibodies
- Move from a RISK/benefit balance to a BENEFIT/risk balance
 - Need to engage the Regulatory Authorities on the changes that the ZAPI project will provide







 Funding for the industrial development and regulatory studies (these One Health emerging diseases are not « markets ») and roadmaps for implementing industrial preparedness ?

 Impact of Nagoya Protocol (NP) for a rapid and free access to the key Genetic Resources, while ensuring fair Access and Benefit Sharing (ABS): how to exempt (re-)emerging infectious diseases strains from the NP obligations ?











Mirriam Tacken Sandra van de Water Lucien van Keulen Jet Kant Jan van Lent Jeroen Kortekaas

-		
	E.m.	

Gleyder Roman-Sosa Aebischer, Andrea Kerstin Wernike <u>Martin Beer</u>





Utrecht University

Ivy Widjaja Berend-Jan Bosch BIAH LyonPhilippe BauduFrederic ReynardNatalia BomchilDidier RozeCatherine CharreyreMarie-Line SajousZahia HannasMichèle SchneiderNathalie MoulianCécile Sigoillot-Claude

BIAH Hannover Alexander Brix Michael Gassel Erik Schacht Konrad Stadler







Zoonoses Anticipation and Preparedness Initiative



Thank you for your attention



This research was performed as part of the Zoonoses Anticipation and Preparedness Initiative (ZAPI project; IMI Grant Agreement n°115760), with the assistance and financial support of IMI and the European Commission, and in-kind contributions from EFPIA partners



